Pyxis Oncology, Inc.
PYXS
$1.04
-$0.02-1.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 16.15M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 16.15M | -- |
| Cost of Revenue | 0.00 | -- | -- | 475.00K | -- |
| Gross Profit | 0.00 | -- | -- | 15.67M | -- |
| SG&A Expenses | 4.37M | 5.31M | 5.37M | 7.45M | 5.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.39M | 23.05M | 19.32M | 20.95M | 17.19M |
| Operating Income | -18.39M | -23.05M | -19.32M | -4.81M | -17.19M |
| Income Before Tax | -37.74M | -21.20M | -17.30M | -3.26M | -15.60M |
| Income Tax Expenses | -2.16M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.57M | -21.20M | -17.30M | -3.26M | -15.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.57M | -21.20M | -17.30M | -3.26M | -15.60M |
| EBIT | -18.39M | -23.05M | -19.32M | -4.81M | -17.19M |
| EBITDA | -17.84M | -22.32M | -18.74M | -3.69M | -16.50M |
| EPS Basic | -0.58 | -0.35 | -0.29 | -0.06 | -0.35 |
| Normalized Basic EPS | -0.17 | -0.22 | -0.18 | -0.04 | -0.22 |
| EPS Diluted | -0.58 | -0.35 | -0.29 | -0.06 | -0.35 |
| Normalized Diluted EPS | -0.17 | -0.22 | -0.18 | -0.04 | -0.22 |
| Average Basic Shares Outstanding | 61.25M | 60.72M | 60.50M | 51.29M | 44.48M |
| Average Diluted Shares Outstanding | 61.25M | 60.72M | 60.50M | 51.29M | 44.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |